

Fig. S2 ERCC6L2 deficiency leads to defective CSR. a RNA-Seq data of Ercc6/2 gene in ex vivo LPS/IL4-activated B cells with the indicated genotypes are showed with zoom-in views of the knockout-regions at bottom. b ERCC6L2 is not required for mouse viability. Numbers of pups are listed, and chi-square test was applied. c CSR to IgG3 in ex vivo LPS-activated B cells with the indicated genotypes. Representative flow cytometry plots are showed. d Size of Ercc6/2^{-/-} spleen is comparable to the WT spleen (left), and the splenic B cell numbers are not affected by ERCC6L2-deficiency (right). Four pairs of Ercc6/2^{-/-} and WT mice are tested, and no significant difference was identified (mean ± SD, two-tail unpaired t-test). e Growth curves of ex vivo LPS/IL4-activated B cells with the indicated genotypes. Data are represented as mean ± SEM from five pairs of Ercc6/2-/- and WT mice. f Cell cycle of ex vivo LPS/IL4-activated B cells with the indicated genotypes. Cell cycle was determined by flow cytometry analysis of incorporated EdU and DNA content. Representative flow cytometry plots of three repeats are showed. g Cell division of ex vivo LPS/IL4-activated B cells with the indicated genotypes. Cell division was monitored by CFSE-incorporation analysis. CSR for each cell division is plotted at bottom. h AID protein levels in ex vivo LPS/IL4-activated B cells with the indicated genotypes. Representative western blot of three repeats is showed. i IgH C gene germline transcript levels in ex vivo LPS/IL4-activated B cells with the indicated genotypes. Representative semi-quantitative RT-PCR result of three repeats is showed. j MA plot shows global RNA expression changes between WT and *Ercc6/2^{-/-}* activated B cells. X axis indicates mean count of normalized reads, while y axis is log2-transformed fold